Effect of Raloxifene on Cerebral Vasospasm Following Experimental Subarachnoid Hemorrhage in Rats

The effect of raloxifene on cerebral vasospasm following experimental subarachnoid hemorrhage (SAH) was investigated in a rat model. Seven groups of seven rats underwent no SAH, no treatment; SAH only; SAH plus vehicle; SAH plus 3 days intraperitoneal raloxifene treatment; SAH plus 4 days intraperit...

Full description

Saved in:

Bibliographic Details
Published in:	Neurologia medico-chirurgica Vol. 47; no. 12; pp. 537 - 542
Main Authors:	GULSEN, Salih, INCI, Servet, YURUK, Sinan, YASAR, Umit, OZGEN, Tuncalp
Format:	Journal Article
Language:	English
Published:	Japan The Japan Neurosurgical Society 2007 THE JAPAN NEUROSURGICAL SOCIETY
Subjects:	Animals cerebral vasospasm Estrogen Antagonists - therapeutic use Male raloxifene Raloxifene Hydrochloride - therapeutic use Rats Rats, Wistar subarachnoid hemorrhage Subarachnoid Hemorrhage - complications Subarachnoid Hemorrhage - pathology Vasospasm, Intracranial - etiology Vasospasm, Intracranial - pathology Vasospasm, Intracranial - prevention & control
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The effect of raloxifene on cerebral vasospasm following experimental subarachnoid hemorrhage (SAH) was investigated in a rat model. Seven groups of seven rats underwent no SAH, no treatment; SAH only; SAH plus vehicle; SAH plus 3 days intraperitoneal raloxifene treatment; SAH plus 4 days intraperitoneal raloxifene treatment; SAH plus 3 days intrathecal raloxifene treatment; and SAH plus 4 days intrathecal raloxifene treatment. The basilar artery cross-sectional areas were measured at 72 or 96 hours following SAH. The results showed raloxifene decreased SAH-induced cerebral vasospasm in all treatment groups, and suggested no difference between intraperitoneal and intrathecal application, or between 3 days and 4 days of raloxifene treatment. The present study demonstrates that raloxifene is a potential therapeutic agent against cerebral vasospasm after SAH.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0470-8105 1349-8029
DOI:	10.2176/nmc.47.537